- AU$2.51bn
- AU$2.52bn
- $17.20m
Mesoblast Ltd expected to post a loss of 15 cents a share - Earnings Preview
Australia's Mesoblast jumps as US FDA grants orphan-drug status to heart drug
Brief: Mesoblast Says FDA Grants Orphan Drug Designation For Revascor
Mesoblast up as FDA grants rare pediatric disease tag to cell therapy
Brief: Mesoblast Says FDA Grants Rare Pediatric Disease Designation For Revascor
Australia's Mesoblast soars after FDA grants cell therapy rare pediatric disease tag
Australia's Mesoblast plunges to record low after discounted placement
Brief: Mesoblast To Raise Up To A$97.0 Mln
Brief: Mesoblast Seeks Trading Halt
Brief: Mesoblast Files For FDA Designations In Congenital Heart Disease
Mesoblast up on deal for late-stage trial of GvHD therapy
Brief: Mesoblast Partners With Blood And Marrow Transplant Clinical Trials Network
Brief: Mesoblast Ltd Says FY Loss Attributable $81.9 Mln
Mesoblast Ltd expected to post a loss of 13 cents a share - Earnings Preview
U.S.-listed Mesoblast shares slide after US FDA rejects cell therapy for children
Mesoblast shares tank after US FDA rejects cell therapy for children (updated)
Mesoblast shares slammed on US FDA blow; set for worst session ever
FDA rejects Mesoblast's cell therapy for bone marrow transplant complications
ASX-listed Mesoblast tanks after US FDA seeks more data for remestemcel-L